Clarevia Ventures Welcomes Margaret Kaczor Andrew as Venture Partner

MADISON, Wis.--(BUSINESS WIRE)--Clarevia Ventures today announced the appointment of Margaret Kaczor Andrew as Venture Partner. In this role, Kaczor Andrew will focus on sourcing, evaluating, and supporting investments across medical devices, clinical technologies, and emerging healthcare platforms.

Kaczor Andrew brings more than 15 years of experience at the intersection of healthcare innovation, capital markets, and clinical adoption. Her background strengthens Clarevia’s ability to identify promising healthcare technologies at their earliest stages and help founders sharpen the path from breakthrough science to patient impact.

“We are fortunate to welcome Margaret to the Clarevia team,” said Jim Adox, Managing Partner at Clarevia. “Her experience, insights, and relationships across healthcare investing will be invaluable as we continue to identify and support transformative healthcare companies. She brings a rigorous understanding of how clinical technologies are evaluated, adopted, and scaled, along with deep relationships in the Chicago area that will further strengthen our footprint in the region.”

Kaczor Andrew spent 15 years at William Blair as a partner and sell-side equity research analyst, with a focus on clinical innovation and the adoption dynamics that drive long-term value creation. She has extensive experience advising investors, management teams, and companies on market strategy, new business opportunities, competitive positioning, and fundraising.

Her work spans a range of clinical areas, with a particular interest in medical technology solutions addressing unmet needs in consumer health tech, cardiology, neurology, diabetes, aesthetics, respiratory care, and ophthalmology. She is known for combining rigorous market analysis with a practical understanding of how technologies move from clinical promise to real-world adoption.

“I’m excited to join Clarevia and work alongside entrepreneurs and investors focused on advancing meaningful healthcare innovation,” said Kaczor Andrew. “There is significant opportunity to better connect clinical insight with investment strategy, and I look forward to helping build companies that deliver both strong returns and improved patient outcomes.”

Kaczor Andrew’s appointment reflects Clarevia’s continued commitment to partnering with founders who need more than capital to transform promising healthcare innovations into companies that can improve patient care. The firm brings disciplined capital, operational rigor, and strategic counsel to founders building in complex clinical markets where clarity, focus, and long-term partnership are critical.

About Clarevia Ventures

Clarevia is a venture capital firm dedicated to turning scientific breakthroughs into life-changing patient outcomes. Founded in 1984, Clarevia partners with founders at the earliest and most overlooked stages, providing the capital, operational rigor, and counsel to usher promising science from discovery to commercialization. Behind companies such as HistoSonics, Neurovance and EarliPoint, Clarevia's mission is to ensure the most important healthcare innovations find a clear path to the patients who need them most.